UAE Inhibitor and Chemotherapy Combination for Resistant Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are inadequate in effectively addressing various types of cancers, particularly in cases where cancers are resistant or refractory to existing therapeutic regimens, and there is a need for new combinations of therapeutic agents to improve patient outcomes while maintaining quality of life.
Innovation Solution
The use of a combination therapy involving an ubiquitin-activating enzyme (UAE) inhibitor, specifically ((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(3-(trifluoromethylthio)phenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino)cyclopentyl)methyl sulfamate, in conjunction with chemotherapeutic agents like carboplatin, oxaliplatin, and docetaxel, to treat cancers such as breast, colorectal, ovarian, lung, and hematological malignancies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapeutic agents are used alone, then treatment simplicity is maintained, but effectiveness against resistant cancers deteriorates
Solution Approach 1:
The patent combines UAE inhibitor with traditional chemotherapeutic agents (platinum-based drugs, taxanes, anthracyclines) into a unified treatment regimen. This merging of therapeutic mechanisms addresses cancer resistance by simultaneously targeting multiple cellular pathways - the UAE inhibitor disrupts protein degradation while chemotherapeutic agents damage DNA or interfere with cell division, creating synergistic anti-cancer effects that overcome single-agent resistance.
2Reliability
If combination therapy with UAE inhibitor and chemotherapeutic agents is used, then cancer treatment effectiveness is improved, but treatment complexity increases
Solution Approach 1:
The patent implements dynamic dosing schedules where the UAE inhibitor and chemotherapeutic agents are administered at different time points and frequencies optimized for maximum efficacy. The regimen adapts to patient response and tolerability, with dosing intervals and sequences carefully calibrated to enhance synergistic effects while managing treatment complexity through evidence-based protocols.
3Productivity
If UAE inhibitor is administered alone, then targeted therapy specificity is maintained, but overall anti-cancer activity is insufficient
Solution Approach 1:
The patent exploits the cancer cell's reliance on the ubiquitin-proteasome system for survival by using UAE inhibitors to block this protective mechanism. Cancer cells depend on efficient protein degradation to manage the high turnover rate required for rapid proliferation; inhibiting UAE disrupts this essential pathway, converting the cancer cell's own survival mechanism into a vulnerability that can be exploited therapeutically, especially when combined with chemotherapeutic agents.
Data Source
Figure 1
Figure 2a
Figure 2b
AI summary
Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an ubiquitin-activating enzyme (UAE) inhibitor such as ((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(3-(trifluoromethylthio)phenyl)pyrazolo [1,5-a]pyrimidin-7-ylamino)cyclopentyl)methyl sulfamate (Compound 1) or a pharmaceutically acceptable salt in combination with one or more chemotherapeutic agents. Also disclosed are medicaments for use in the treatment of cancer.